---
document_datetime: 2025-12-02 05:23:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sevelamer-carbonate-winthrop.html
document_name: sevelamer-carbonate-winthrop.html
version: success
processing_time: 0.3711587
conversion_datetime: 2025-12-25 00:00:31.395397
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)

[RSS](/en/individual-human-medicine.xml/66965)

##### Authorised

This medicine is authorised for use in the European Union

sevelamer carbonate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sevelamer carbonate Winthrop is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:

- adult patients on dialysis (a technique to remove unwanted substances from the blood);
- adults and children from 6 years of age with chronic (long term) kidney disease.

Sevelamer carbonate Winthrop should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease. It contains the active substance sevelamer carbonate.

Expand section

Collapse section

## How is Sevelamer carbonate Winthrop used?

Sevelamer carbonate Winthrop is available as tablets (800 mg) and as powder (800 mg and 2.4 g) to be taken 3 times a day with meals.

The dose to take depends on the patient's level of blood phosphate and, for children, their height and weight. Sevelamer carbonate Winthrop must not be taken on an empty stomach and patients should keep to their prescribed diets.

The medicine can only be obtained with a prescription. For more information about using Sevelamer carbonate Winthrop, see the package leaflet or contact your doctor or pharmacist.

## How does Sevelamer carbonate Winthrop work?

The active substance in Sevelamer carbonate Winthrop, sevelamer carbonate, is a phosphate binder. When taken with meals, it attaches in the gut to phosphate from the food, thereby preventing the phosphate from being absorbed into the body and helping to reduce phosphate levels in the blood.

## What benefits of Sevelamer carbonate Winthrop have been shown in studies?

Sevelamer carbonate Winthrop has been shown in studies to be effective at lowering levels of blood phosphate in patients with hyperphosphataemia.

In two main studies in 110 adults with kidney disease who were on dialysis, Sevelamer carbonate Winthrop brought phosphate levels down to around 1.5-1.6 mmol/l (which is within or close to the normal range) and was as effective as another approved medicine Renagel. In a third main study in 49 adults who were not on dialysis, Sevelamer carbonate Winthrop reduced phosphate levels from 2.0 mmol/l to 1.6 mmol/l.

Finally, a main study also showed that Sevelamer carbonate Winthrop was effective at lowering phosphate levels in 100 children: children who took Sevelamer carbonate Winthrop had a greater reduction in phosphorous (0.87 mg/dl) than those taking placebo (a dummy treatment) who had a rise in phosphorous of 0.04 mg/dl.

## What are the risks associated with Sevelamer carbonate Winthrop?

The most common side effects with Sevelamer carbonate Winthrop (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, upper abdominal (belly) pain and constipation. For the full list of side effects of Sevelamer carbonate Winthrop, see the package leaflet.

Sevelamer carbonate Winthrop must not be used in people with low blood phosphate levels or with bowel obstruction (a blockage in the gut). For the full list of restrictions, see the package leaflet.

## Why is Sevelamer carbonate Winthrop approved?

Studies show that Sevelamer carbonate Winthrop is effective at reducing levels of blood phosphate in patients with hyperphosphataemia, and its side effects are considered manageable. The European Medicines Agency therefore decided that Sevelamer carbonate Winthrop's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sevelamer carbonate Winthrop?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sevelamer carbonate Winthrop have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sevelamer carbonate Winthrop are continuously monitored. Side effects reported with Sevelamer carbonate Winthrop are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sevelamer carbonate Winthrop

Sevelamer carbonate Winthrop received a marketing authorisation valid throughout the EU on 15 January 2015. This authorisation was based on the authorisation granted to Renvela in 2009 ('informed consent').

Sevelamer carbonate Winthrop : EPAR - Medicine overview

Reference Number: EMA/213714/2019

English (EN) (81.62 KB - PDF)

**First published:** 13/03/2015

**Last updated:** 22/07/2019

[View](/en/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-190)

български (BG) (111.01 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/bg/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_bg.pdf)

español (ES) (81.37 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/es/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_es.pdf)

čeština (CS) (105.29 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/cs/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_cs.pdf)

dansk (DA) (79.33 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/da/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_da.pdf)

Deutsch (DE) (82.1 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/de/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_de.pdf)

eesti keel (ET) (79.09 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/et/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_et.pdf)

ελληνικά (EL) (118.79 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/el/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_el.pdf)

français (FR) (82.02 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/fr/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_fr.pdf)

hrvatski (HR) (98.48 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/hr/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_hr.pdf)

italiano (IT) (79.46 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/it/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (108.44 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/lv/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (104.5 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/lt/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_lt.pdf)

magyar (HU) (100.32 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/hu/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_hu.pdf)

Malti (MT) (106.09 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/mt/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_mt.pdf)

Nederlands (NL) (80.6 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/nl/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_nl.pdf)

polski (PL) (112.98 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/pl/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_pl.pdf)

português (PT) (81.2 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/pt/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_pt.pdf)

română (RO) (103.47 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/ro/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_ro.pdf)

slovenčina (SK) (103.27 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/sk/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_sk.pdf)

slovenščina (SL) (98.01 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/sl/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_sl.pdf)

Suomi (FI) (78.85 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/fi/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_fi.pdf)

svenska (SV) (80.72 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

22/07/2019

[View](/sv/documents/overview/sevelamer-carbonate-winthrop-epar-medicine-overview_sv.pdf)

## Product information

Sevelamer carbonate Winthrop : EPAR - Product Information

English (EN) (705.58 KB - PDF)

**First published:** 13/03/2015

**Last updated:** 18/12/2024

[View](/en/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-817)

български (BG) (680.07 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/bg/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_bg.pdf)

español (ES) (727.75 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/es/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_es.pdf)

čeština (CS) (612.91 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/cs/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_cs.pdf)

dansk (DA) (499.94 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/da/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_da.pdf)

Deutsch (DE) (477.81 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/de/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_de.pdf)

eesti keel (ET) (663.48 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/et/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_et.pdf)

ελληνικά (EL) (612.69 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/el/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_el.pdf)

français (FR) (629.85 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/fr/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_fr.pdf)

hrvatski (HR) (617.46 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/hr/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_hr.pdf)

íslenska (IS) (503.08 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/is/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_is.pdf)

italiano (IT) (567.72 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/it/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_it.pdf)

latviešu valoda (LV) (555.35 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/lv/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_lv.pdf)

lietuvių kalba (LT) (599.72 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/lt/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_lt.pdf)

magyar (HU) (579.59 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/hu/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_hu.pdf)

Malti (MT) (670.6 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/mt/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_mt.pdf)

Nederlands (NL) (546.84 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/nl/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_nl.pdf)

norsk (NO) (558.46 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/no/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_no.pdf)

polski (PL) (647.03 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/pl/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_pl.pdf)

português (PT) (472.05 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/pt/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_pt.pdf)

română (RO) (626.92 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/ro/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_ro.pdf)

slovenčina (SK) (599.55 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/sk/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_sk.pdf)

slovenščina (SL) (579.53 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/sl/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_sl.pdf)

Suomi (FI) (457.02 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/fi/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_fi.pdf)

svenska (SV) (482.55 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

18/12/2024

[View](/sv/documents/product-information/sevelamer-carbonate-winthrop-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0038 12/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sevelamer carbonate Winthrop : EPAR - All Authorised presentations

English (EN) (10.19 KB - PDF)

**First published:** 13/03/2015

**Last updated:** 16/08/2019

[View](/en/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-281)

български (BG) (34.32 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/bg/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_bg.pdf)

español (ES) (9.74 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/es/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.02 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/cs/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (9.21 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/da/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (9.64 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/de/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.87 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/et/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.15 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/el/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_el.pdf)

français (FR) (9.27 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/fr/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.23 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/hr/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (9.17 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/is/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.62 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/it/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (30.9 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/lv/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (30.86 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/lt/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.61 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/hu/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (29.94 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/mt/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (9.71 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/nl/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (9.45 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/no/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.89 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/pl/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_pl.pdf)

português (PT) (9.52 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/pt/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_pt.pdf)

română (RO) (30.64 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/ro/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.65 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/sk/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.26 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/sl/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (9.29 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/fi/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (9.6 KB - PDF)

**First published:**

13/03/2015

**Last updated:**

16/08/2019

[View](/sv/documents/all-authorised-presentations/sevelamer-carbonate-winthrop-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva) Active substance sevelamer carbonate International non-proprietary name (INN) or common name sevelamer carbonate Therapeutic area (MeSH)

- Hyperphosphatemia
- Renal Dialysis

Anatomical therapeutic chemical (ATC) code V03AE02

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus &gt; 1.78 mmol/L.

Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

## Authorisation details

EMA product number EMEA/H/C/003971 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail 94250 Gentilly France

Opinion adopted 20/11/2014 Marketing authorisation issued 15/01/2015 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sevelamer carbonate Winthrop : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (204.8 KB - PDF)

**First published:** 28/05/2015

**Last updated:** 18/12/2024

[View](/en/documents/procedural-steps-after/sevelamer-carbonate-winthrop-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sevelamer carbonate Zentiva-H-C-PSUSA-00002697-201810 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/462037/2019

English (EN) (68.1 KB - PDF)

**First published:** 06/09/2019

[View](/en/documents/scientific-conclusion/sevelamer-carbonate-zentiva-h-c-psusa-00002697-201810-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Sevelamer carbonate Zentiva-H-C-3971-WS-0965 : EPAR - Scientific Discussion - Variation

Adopted

Reference Number: EMA/352101/2017

English (EN) (802.77 KB - PDF)

**First published:** 26/07/2017

**Last updated:** 26/07/2017

[View](/en/documents/variation-report/sevelamer-carbonate-zentiva-h-c-3971-ws-0965-epar-scientific-discussion-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Sevelamer carbonate Zentiva (WS/965)

Adopted

Reference Number: EMA/CHMP/310511/2017

English (EN) (68.88 KB - PDF)

**First published:** 22/05/2017

**Last updated:** 22/05/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sevelamer-carbonate-zentiva-ws965_en.pdf)

Sevelamer carbonate Zentiva-H-C-PSUSA-00002697-201510 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/571186/2016

English (EN) (67.67 KB - PDF)

**First published:** 25/08/2016

**Last updated:** 25/08/2016

[View](/en/documents/scientific-conclusion/sevelamer-carbonate-zentiva-h-c-psusa-00002697-201510-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Sevelamer carbonate Zentiva : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/473530/2014

English (EN) (997.76 KB - PDF)

**First published:** 13/03/2015

**Last updated:** 13/03/2015

[View](/en/documents/assessment-report/sevelamer-carbonate-zentiva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sevelamer carbonate Zentiva

Adopted

Reference Number: EMA/CHMP/703681/2014

English (EN) (71.08 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 21/11/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sevelamer-carbonate-zentiva_en.pdf)

#### News on Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2024

## Share this page

[Back to top](#main-content)